It has long been accepted that low intensity electricity has the potential to influence and alter biological and physiological processes. Research has shown that micro-current has the greatest potential of all present electrical stimulation based therapies. Synapse believes that identifying exactly how micro-current therapy works is pivotal to delivering the optimal treatment. Our product range reflects this philosophy.

Cellular activity and intercellular communication is regulated chemically and electrically and this biological communication process is essential to the maintenance of most functional physiological processes and activity. However, research has suggested that stimuli such as an injury or trauma can cause, in simple terms, an electro-chemical disorder which can stop or slow down a normal physiological process, such as healing or indeed cause an illness. The supposition behind the mechanism of micro-current therapy is that this failure of this physiological process does not always result in the cells or cell groups being fundamentally spoiled but rather a critical communication pathway between cells, the molecular transfer between cells or messenger proteins on cells has been disrupted. The passing of a low ampere electric current sequence specific to the function and/or characteristics of a given cell type or operation of the cell membrane (a key interaction point of all cells) to the damaged area works to ignite a pathways between damaged or affected cells or groups of cells.

Measurable research outcomes also indicates that a controlled and cell specific micro-current application stimulates the production of Adenosine Tri-Phosphate (ATP), restores the intra/extra-cellular sodium, potassium and calcium balance and increases the production of hydroxyprolin. In addition, it results in a significant increase in the uptake of amino-isobutyric acid which is essential for protein synthesis and trans-membrane transport. It has also been suggested that the recovery of the cell wall prevents leakage of pain-causing substances (histamine, bradykinine, lactic acid) which results in reduction of pain. This may explain why patients undergoing the Accel Heal treatment have reported a significant reduction in pain levels. The Accel Heal unit was tested in an independently conducted clinical trial on subjects with non-healing chronic wounds and showed significant improvements in wound closure, pain and exudate levels.

Click here to view Quicktime animation of the (simplified) science explained